54322-65-5

Usage

Uses

Used in Organic Synthesis:
Cyclopropylacetyl chloride is used as a reagent to introduce the cyclopropylacetyl group into organic molecules for [application reason], enhancing the properties and functionalities of these molecules in various chemical reactions.
Used in Pharmaceutical Production:
In the pharmaceutical industry, cyclopropylacetyl chloride is used as a key intermediate in the synthesis of various drugs, contributing to the development of new medications with specific therapeutic effects.
Used in Agrochemical Production:
Cyclopropylacetyl chloride is employed in the agrochemical sector as a precursor for the synthesis of pesticides and other crop protection agents, aiming to improve agricultural productivity and crop protection.
Used in Specialty Chemicals Synthesis:
Cyclopropylacetyl chloride is also utilized in the synthesis of specialty chemicals across different industries, serving as a versatile building block for the creation of unique chemical entities with specific applications.

Upstream product

• 5239-82-7 cyclopropylacetic acid 
• 6542-60-5 2-cyclopropylacetonitrile 
• 2516-33-8 Cyclopropylmethanol 
• 143-33-9 sodium cyanide 

Downstream Products

• 5687-69-4 2-cyclopropyl-N-phenylacetamide 
• 34108-21-9 methyl cyclopropylacetate 
• 59698-20-3 5-cyclopropyl-pyrimidin-2,4-(1H,3H)-dione 
• 59698-21-4 5-cyclopropyl-2-thio-2,3-dihydropyrimidine-2,4(1H,3H)-dione 
• 1254977-57-5 3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254977-70-2 8-chloro-3-cyclopropylmethyl-7-[4-phenyl-piperidin-1-yl]-[1,2,4]triazolo[4,3-a]pyridine 
• 1254977-46-2 3-cyclopropylmethyl-7-(4-fluoro-4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1258292-13-5 2,6-dichloro-N-(2-(2-cyclopropylacetamido)pyridin-4-yl)benzamide 
• 1455029-00-1 3-(cyclopropylmethyl)-N-(((1S,2S)-2-(4-fluorophenyl)cyclopropyl)methyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-7-amine 
• 1455029-03-4 2-cyclopropyl-N'-(4-((((1S,2S)-2-(4-fluorophenyl)-cyclopropyl)methyl)amino)-3-(trifluoromethyl)pyridin-2-yl)acetohydrazide 
• 1432498-53-7 N-methyl-N-phenyl-4-cyclopropyl-2,3-butadienamide 
• 1084897-40-4 (S)-N-(1-cyanocyclopropyl)-5-cyclopropyl-4,4-difluoro-2-((S)-2,2,2-trifluoro-1-phenylethylamino)pentanamide 
• 1084897-86-8 (S)-5-cyclopropyl-4,4-difluoro-2-((S)-2,2,2-trifluoro-1-phenylethylamino)pentanoic acid 
• 1017933-32-2 (2S)-2-benzyloxycarbonylamino-4,4-difluoro-5-cyclopropylpentanoic acid methyl ester 

Relevant academic research and scientific papers

Identification of cyclopropylacetyl-(r)-carnitine, a unique chemical marker of the fatally toxic mushroom russula subnigricans

A toxic mushroom, Russula subnigricans, causes fatal poisoning by mistaken ingestion. In spite of the potent bioactivity, the responsible toxin had not been identified for about 50 years since its first documentation. Recently, we isolated an unstable toxin and determined the structure. The slow elucidation was partly due to the instability of the toxin and also due to misidentification of R. subnigricans for similar mushrooms. To discriminate genuine Russula subnigricans from similar unidentified Russula species, we searched for a unique chemical marker contained in the mushroom. Cyclopropylacetyl-(R)-carnitine specific to R. subnigricans was identified as a novel compound whose 1H-NMR signals appearing in the upfield region were easily recognizable among the complicated signals of the crude extract.

Photooxidation of N,N'-Diacylindigo Dyes

Irradiation of N,N'-diacylindigo dyes in the presence of oxygen resulted in an unusual oxygen insertion/acyl transfer reaction.While this process occurred over many weeks at room temperature, at 100 deg C it was complete in a few hours.In some cases the y

ANTI-OSTEOARTHRITIS HYDANTOIN COMPOUNDS AND RELATED COMPOSITIONS AND METHODS

This invention provides hydantoin compounds that inhibit both aggrecanase 1 (Adamts4) and aggrecanase 2 (Adamts5). This invention also provides related compositions and methods for treating inflammatory diseases, diseases involving degradation of cartilage, and diseases involving the disruption of cartilage homeostasis.

A Diverse Library of Chiral Cyclopropane Scaffolds via Chemoenzymatic Assembly and Diversification of Cyclopropyl Ketones

Chiral cyclopropane rings are key pharmacophores in pharmaceuticals and bioactive natural products, making libraries of these building blocks a valuable resource for drug discovery and development campaigns. Here, we report the development of a chemoenzymatic strategy for the stereoselective assembly and structural diversification of cyclopropyl ketones, a highly versatile yet underexploited class of functionalized cyclopropanes. An engineered variant of sperm whale myoglobin is shown to enable the highly diastereo- and enantioselective construction of these molecules via olefin cyclopropanation in the presence of a diazoketone carbene donor reagent. This biocatalyst offers a remarkably broad substrate scope, catalyzing this reaction with high stereoselectivity across a variety of vinylarene substrates as well as a range of different α-aryl and α-alkyl diazoketone derivatives. Chemical transformation of these enzymatic products enables further diversification of these molecules to yield a collection of structurally diverse cyclopropane-containing scaffolds in enantiopure form, including core motifs found in drugs and natural products as well as novel structures. This work illustrates the power of combining abiological biocatalysis with chemoenzymatic synthesis for generating collections of optically active scaffolds of high value for medicinal chemistry and drug discovery.

MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES

The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT2A/mGlu2Receptor Complex

We report the synthesis of the first series of heterobivalent ligands targeting the putative heteromeric 5-HT2A/mGlu2 receptor complex, based on the 5-HT2A antagonist MDL-100,907 and the mGlu2 ago-PAM JNJ-42491293. The functional properties of monovalent and heterobivalent ligands were characterized in 5-HT2A-, mGlu2/Gqo5-, 5-HT2A/mGlu2-, and 5-HT2A/mGlu2/Gqo5-expressing HEK293 cells using a Ca2+ imaging assay and a [3H]ketanserin binding assay. Pronounced functional crosstalk was observed between the two receptors in 5-HT2A/mGlu2 and 5-HT2A/mGlu2/Gqo5 cells. While the synthesized monovalent ligands retained the 5-HT2A antagonist and mGlu2 ago-PAM functionalities, the seven bivalent ligands inhibited 5-HT-induced responses in 5-HT2A/mGlu2 cells and both 5-HT- and Glu-induced responses in 5-HT2A/mGlu2/Gqo5 cells. However, no definitive correlation between the functional potency and spacer length of the ligands was observed, an observation substantiated by the binding affinities exhibited by the compounds in 5-HT2A, 5-HT2A/mGlu2, and 5-HT2A/mGlu2/Gqo5 cells. In conclusion, while functional crosstalk between 5-HT2A and mGlu2 was demonstrated, it remains unclear how these heterobivalent ligands interact with the putative receptor complex.

Decarboxylative Borylation of mCPBA-Activated Aliphatic Acids

A decarboxylative borylation of aliphatic acids for the synthesis of a variety of alkylboronates has been developed by mixing m-chloroperoxybenzoic acid (mCPBA)-activated fatty acids with bis(catecholato)diboron in N,N-dimethylformamide (DMF) at room temperature. A radical chain process is involved in the reaction which initiates from the B-B bond homolysis followed by the radical transfer from the boron atom to the carbon atom with subsequent decarboxylation and borylation.

TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF

Provided are novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e. g., inflammatory diseases, immune-mediated diseases or cancer).

Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus

Vancomycin-resistant enterococci (VRE) are the second leading cause of hospital-acquired infections (HAIs) attributed to a drug-resistant bacterium in the United States, and resistance to the frontline treatments is well documented. To combat VRE, we have repurposed the FDA-approved carbonic anhydrase drug acetazolamide to design potent antienterococcal agents. Through structure-activity relationship optimization we have arrived at two leads possessing improved potency against clinical VRE strains from MIC = 2 μg/mL (acetazolamide) to MIC = 0.007 μg/mL (22) and 1 μg/mL (26). Physicochemical properties were modified to design leads that have either high oral bioavailability to treat systemic infections or low intestinal permeability to treat VRE infections in the gastrointestinal tract. Our data suggest the intracellular targets for the molecules are putative α-carbonic and γ-carbonic anhydrases, and homology modeling and molecular dynamics simulations were performed. Together, this study presents potential anti-VRE therapeutic options to provide alternatives for problematic VRE infections.

PROTEASOME INHIBITORS

The disclosure provides proteasome inhibitors that can be used to halt cell division of rapidly dividing cells by preventing the degradation of cell cycle-regulating proteins, such as cyclins, cyclin-dependent kinase inhibitors, and p53. The proteasome in